This series on “Novel Developments in the Multimodality Treatment of Esophageal Cancer” was edited by Dr. Bas Wijnhoven and Dr. Sjoerd Lagarde, from Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands; and Prof. Florian Lordick, from Universitätsklinik Leipzig, Leipzig, Germany.

At some point in time, more than 50% of patients present with metastatic disease. Although survival remains dismal in the majority of these patients, there have been important developments in the treatment of dysphagia and a well selected subgroup of patients might be offered more aggressive multimodal therapy. Taken together, the treatment of esophageal cancer is rapidly evolving with novel multimodal developments. This series highlighted the recent progress that has been made and hopefully this will translate into a brighter future for our patients.

Disclosure:
The series “Novel Developments in the Multimodality Treatment of Esophageal Cancer” was commissioned by the editorial office, Annals of Esophagus without any sponsorship or funding. Bas Wijnhoven, Sjoerd Lagarde, and Florian Lordick served as the unpaid Guest Editors for this series.